Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions
Hypophosphatasia
Interventions
DRUG

asfotase alfa

Trial Locations (23)

3052

Royal Children'S Hospital Melbourne, Parkville

4101

Lady Cilento Children's Hospital, South Brisbane

11211

King Faisal Specialist Hospital and Research Center, Riyadh

15224

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

16059

Uludag University, Bursa

16147

Istituto Giannina Gaslini, Genova

28009

Hospital Infantil Universitario Nino Jesus, Madrid

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

75743

Necker Hospital, Paris

94609

Children's Hospital & Research Center Oakland, Oakland

97080

Universitätskinderklinikum Würzburg, Würzburg

117036

Federal State Budgetary Institution, Moscow

R3A 1S1

Health Sciences Centre Winnipeg, University of Manitoba, Winnipeg

Unknown

Chu de Toulouse, Toulouse

00165

Ospedale Pediatrico Bambino Gesù, Roma

811-3195

Fukuoka Higashi Medical Hospital, Koga

920-8530

Ishikawa Prefectural Hospital, Kanazawa

241-0811

St. Marianna University School of Medicine, Yokohayama City Seibu Hospital, Yokohama

160-0023

Tokyo Medical University Hospital, Shinjuku

336-8522

Saitama Municipal Hospital, Saitama

B4 6NH

Birmingham Children's Hospital, Birmingham

M13 9WL

Royal Manchester Children'S Hospital, Manchester

S10 2TH

Sheffield Children'S Hospital, Sheffield

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY